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A growing body of evidence indicates that the expression of TERT, the catalytic subunit of telomerase, 
is a biological marker of progression in several cancers. We investigated the predictive and prognostic 
role of TERT levels and telomere length in tissues and peripheral blood in patients with head and neck 
squamous cell carcinoma (HNSCC). High TERT levels in cancer tissues were independently associated 
with worse response to therapy (odds ratio [OR]:6.26), regional failure (hazard ratio [HR]:5.75), 
progression (HR:2.12), and death (HR:3.53). Longer telomeres in the mucosa surrounding the tumor 
(SM) were independently associated with a lower risk of mucosal failure (HR:0.39). While telomere 
length in peripheral blood mononuclear cells (PBMC) significantly decreased with age, no correlation 
was found between age and telomere length in SM. No associations were found between TERT levels 
in plasma and telomere length in PBMC and the prognostic variables. High levels of TERT transcripts 
in cancer cells represent a reliable prognostic marker for identifying HNSCC patients with risk of 
progression. The altered relationship of telomere length to age in SM compared with PBMC suggests 
that in a subset of cases the phenotypically normal SM constitutes an acquired telomere-shortened 
epithelial field prone to genetic instability.
Head and neck squamous cell carcinomas (HNSCCs) are a group of neoplasms developing in epithelia lining 
the upper aero-digestive tract (UADT, i.e. the oral cavity, the oropharynx, the hypopharynx, and the larynx). 
HNSCCs are caused predominantly by chemically (through tobacco and/or alcohol exposure) or virally induced 
carcinogenesis after infection by human papillomavirus (HPV)1. Tobacco- and alcohol-related HNSCC and 
HPV-driven HNSCC are two biologically and clinically distinct entities, with the latter being associated with low 
mutational burden and significantly longer overall survival2. While HPV-driven HNSCCs show wild-type TP53 
sequences and the presence of viral oncogenes E6 and E7, HPV-negative disease more commonly harbors TP53 
mutations and chromosomal instability. However, about 20% of HPV-negative HNSCCs harbor wild-type TP53 
sequences, low numbers of genetic mutations and low chromosomal instability, thus representing a subgroup of 
genetically distinct HPV-negative disease3.
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Moreover, next-generation sequencing techniques have revealed the intricate genetic makeup of HNSCC4. 
Both HPV-driven and non-HPV-driven tumors can indeed be subclassified by gene expression profiling, and 
different sets of mutations have been observed among tumors from different individuals with the same type of 
cancer. Additionally, recent studies have demonstrated significant intratumoral heterogeneity whereby a single 
tumor contains a diverse collection of cells harboring distinct molecular signatures5. Thus, despite possessing 
similar histological characteristics, HNSCC is a tremendously heterogeneous disease.
To date, there are no robust molecular markers useful in planning management for patients with HNSCC and, 
despite their intrinsic heterogeneity, all HNSCCs are similarly treated1. Consequently, even within an individual 
subsite, the clinical course of HNSCC, including response to therapy, disease progression and metastasis, varies 
widely with outcome being poorly predicted by clinical or histological features.
Although numerous genetic alterations involving a variety of different pathways contribute to the develop-
ment and progression of HNSCC, 85% of cancers acquire the capability to replicate indefinitely through the 
re-activation of telomerase, a ribonucleoprotein complex containing an internal RNA component and a catalytic 
protein, TERT, with telomere specific reverse transcriptase activity6.
Despite somewhat divergent conclusions7,8, a substantial body of studies have uncovered novel extra-telomeric 
non-canonical functions of telomerase, many of which affect cellular processes including signaling pathways for 
the regulation of cell survival, resistance to stress, and apoptosis9. Importantly, through the interaction of TERT 
with the Wnt/β-catenin and the NF-kB signaling pathways, the expression of telomerase may affect cancer inva-
siveness and metastasis10–12. Thus, levels of telomerase in cancer cells may influence the response to treatment as 
well as cancer progression and metastasis, making it a potentially attractive predictive and prognostic marker. 
Prior to telomerase activation, telomere dynamics plays an essential role in the early stage of carcinogenesis. 
Telomere attrition appears indeed to be a driver of genetic instability and short telomeres are consistently found 
in HNSCC precursors and in mucosa adjacent to pre-neoplastic areas and invasive cancer13,14.
Moreover, mechanistic studies have clearly demonstrated that mammalian cells lacking telomerase activity 
show progressive telomere shortening that, in late generation mice, results in end-end chromosome fusions and 
deletions upon irradiation15,16. Thus, high levels of TERT, by stabilizing longer telomeres may indirectly confer 
cancer cells with an increased resistance to radiotherapy and contribute to tumor progression.
Our previous research has demonstrated high TERT levels in cancer tissues to be associated with progression 
at regional and distant sites and higher risk of death, and short telomeres in the mucosa surrounding the tumor 
(SM) to predict a higher risk of mucosal failure13. These observations have raised several questions: are shortened 
telomeres in SM the consequence of greater cell proliferation or are they linked to an individual’s constitutive tel-
omere length? What is the significance of telomere length in peripheral blood mononuclear cells (PBMC)? What 
is the significance of cell-free circulating plasma TERT mRNA? To answer these questions, in this new prospective 
study, we also collected blood samples in addition to cancer tissue and normal SM. We estimated telomere length 
and TERT levels and their relationship in cancer tissue, SM, and peripheral blood, and we investigated their pre-
dictive and prognostic roles in patients with HNSCC.
Results
Demographic and clinical characteristics of patients. The clinical characteristics of the 101 patients 
are summarized in Supplementary Table 1. The study group had a median age of 65 years (range, 28–87 years) 
at presentation and included 74 (73%) male and 27 (27%) female patients. The female prevalence was signifi-
cantly lower among tumors developing from the hypopharynx/larynx (P = 0.003; Supplementary Table 1). The 
majority of patients were ever smokers (73%) and ever drinkers (59%). However, ever drinking was less frequent 
in patients with oropharyngeal SCC (P = 0.018; Supplementary Table 1), which overall were more commonly 
diagnosed in advanced stage (P = 0.003; Supplementary Table 1). Six percent (n = 4/66) of patients submitted to 
primary surgical treatment had positive/close margins. Among the 66 patients treated with upfront surgery, 28 
(42%) received adjuvant (chemo)radiotherapy.
Telomere length in tumor, SM, and PBMC. Median telomere length in tumor cells, SM, and PBMC 
according to descriptive characteristics are reported in Table 1. The telomere length in tumor cells and in PBMC 
was not significantly associated with any of the descriptive variables investigated herein. On the other hand, 
telomere length in SM was significantly shorter in male patients (P = 0.032) and in ever drinkers (P = 0.004). No 
correlation was found between age and telomere length (Table 1). However, a finer classification of age revealed 
that telomere length in PBMC, but not in tumor and SM (Fig. 1A,B), significantly decreased with age (P = 0.037; 
Fig. 1C); no correlation was found between telomere length in SM and PBMC (r-Spearman = 0.22; P = 0.107). 
Additionally, no correlation existed between telomere length in SM and in the tumor, nor between telomere 
length in PBMC and in the tumor.
TERT levels in tumor, SM, and plasma. Median levels of TERT in tumor, SM, and plasma according to 
descriptive characteristics are reported in Table 1. TERT levels in tumor cells were significantly higher in females 
(P = 0.023) and in patients with advanced stage disease (P < 0.001) and neck metastases (P < 0.001). TERT levels 
in SM were significantly higher in patients with cancer of the hypopharynx/larynx (P = 0.013) and in those with 
advanced stage disease (P = 0.002). Among oropharyngeal cancers, patients with HPV-driven oropharyngeal 
cancer reported higher TERT levels in SM (P < 0.001). Circulating TERT levels in plasma were estimated in 97 
cases; 42 cases, including 18 of those who had high tumor TERT levels, were negative for TERT mRNA. Overall, 
the analysis of TERT levels in plasma did not yield significant results (Table 1).
Response to treatment. The correlation between telomere length and TERT levels with the response to 
treatment is summarized in Supplementary Table 2. In a multivariate analysis adjusted for gender, age and clinical 
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variables it emerged that short telomeres in SM and high TERT levels in tumor tissue were significantly associated 
with worse treatment response (OR = 4.19, 95% CI: 1.01–17.47, P = 0.049 and OR = 6.26, 95% CI: 1.10–35.51, 
P = 0.038; respectively).
n (%)
Telomere length TERT level
Tumor(n = 101) SM(n = 96) PBMC(n = 61) Tumor(n = 93) SM(n = 88) Plasma(n = 94)
Gender
  Male 74 (73.3) 1.05 1.04 0.88 1128 427 32
  Female 27 (26.7) 1.04 1.17 0.83 1946 437 0
Kruskall-Wallis test p = 0.892 p = 0.032 p = 0.856 p = 0.023 p = 0.993 p = 0.175
Age (years)
  <60 30 (29.7) 1.10 1.06 0.90 1725 454 42
  60–69 37 (36.6) 0.99 1.04 0.83 1356 401 37
  ≥70 34 (33.7) 1.11 1.10 0.82 779 446 0
  Kruskall-Wallis test p = 0.301 p = 0.970 p = 0.260 p = 0.116 p = 0.907 p = 0.654
Smoking habits
  Never 27 (26.7) 1.11 1.14 0.81 1524 349 27
  Ever 74 (73.3) 1.04 1.04 0.89 1228 465 29
  Kruskall-Wallis test p = 0.332 p = 0.341 p = 0.308 p = 0.510 p = 0.338 p = 0.799
Drinking habits
  Never 41 (40.6) 1.09 1.17 0.87 1425 410 31
  Ever 60 (59.4) 1.03 1.01 0.88 1269 465 17
  Kruskall-Wallis test p = 0.645 p = 0.004 p = 0.721 p = 0.821 p = 0.841 p = 0.759
Cancer site
  Oral cavity 27 (26.7) 1.15 1.16 1.08 1090 338 37
  Oropharynx 22 (21.8) 1.06 1.08 0.88 1679 404 24
  Hypopharynx/Larynx 52 (51.5) 0.99 1.03 0.85 964 527 23
  Kruskall-Wallis test p = 0.095 p = 0.296 p = 0.479 p = 0.108 p = 0.013 p = 0.912
cT
  T1-T2 52 (51.5) 1.07 1.13 0.84 739 384 30
  T3-T4 49 (48.5) 1.04 1.04 0.89 1559 648 17
  Kruskall-Wallis test p = 0.510 p = 0.168 p = 0.119 p = 0.010 p = 0.094 p = 0.392
cN
  Negative 50 (49.5) 1.07 1.03 0.84 384 359 50
  Positive 51 (50.5) 1.03 1.09 0.89 1679 632 14
  Kruskall-Wallis test p = 0.825 p = 0.193 p = 0.214 p < 0.001 p = 0.056 p = 0.351
Stage
  I-II 36 (35.6) 1.07 1.04 0.85 346 297 49
  III-IV 65 (64.4) 1.04 1.08 0.88 1679 632 17
  Kruskall-Wallis test p = 0.737 p = 0.985 p = 0.452 p < 0.001 p = 0.002 p = 0.403
Gradinga
  1–2 59 (72.0) 1.04 1.04 0.82 1295 398 46
  3 23 (28.0) 1.11 1.06 0.89 1501 948 0
  Kruskall-Wallis test p = 0.649 p = 0.485 p = 0.520 p = 0.112 p = 0.043 p = 0.135
HPV-driven oropharyngeal carcinoma
  No 12 (54.5) 0.85 1.02 0.89 1604 141 28
  Yes 10 (45.5b) 1.20 1.10 0.82 1946 1277 15
  Kruskall-Wallis test p = 0.129 p = 0.199 p = 0.124 p = 0.396 p < 0.001 p = 1.000
Primary Treatment
  Surgery+/− (CT)RT 66 (64.4) 1.07 1.13 0.84 911 384 9
  (CT)RT 35 (35.6) 1.03 1.04 0.89 1502 482 39
  Kruskall-Wallis test p = 0.272 p = 0.319 p = 0.456 p = 0.192 p = 0.449 p = 0.942
Table 1. Distribution of 101 patients with head and neck cancer and median values of telomere length and 
telomerase reverse transcriptase (TERT) level according to patient and tumor characteristics. SM: Surrounding 
mucosa; PBMC: Peripheral blood monoclonal cells; (CT)RT: (chemo)radiotherapy. aThe figures do not add up 
to the total because of some missing values. bThe prevalence of HPV-driven oropharyngeal carcinoma is higher 
than has been previously reported and reflects the increasing trend in prevalence over the years.
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Time-to-event analysis. During a median follow-up time of 20 months (interquartile range, 9–35 months), 
27 patients (26.7%) had mucosal failure, 18 (17.8%) regional failures and 5 (5.0%) distant metastases. All patients 
with positive margins after surgery received adjuvant chemoradiation, and none developed mucosal failure. 
Overall, 39 patients (38.6%) experienced a PFS event and 32 patients (31.7%) died (24 deaths were attributable 
to cancer).
Short telomeres in SM were associated with worse mucosal control (5-year mucosal control = 62% vs 81% in 
patients with telomere length in SM < 1.0675 vs > 1.0675; P = 0.027; Fig. 2A). This association was confirmed by 
multivariate analysis (Table 2) after adjustment for clinical variables, with a HR for mucosal failure of 2.57 (95% 
CI: 1.03–6.42; P = 0.044). Telomere length in tumor tissue and PBMC was not associated with any of the clinical 
endpoints (Table 2). High TERT levels in tumor tissue were consistently associated with worse prognosis: 5-year 
OS was 69% in patients with TERT levels < 1318 and 44% in those with TERT levels > 1318 (P = 0.009; Fig. 3E). 
Corresponding figures for 5-year PFS were 60% and 45% (P = 0.033 Fig. 3D). This difference was likely due to 
worse regional control in patients with elevated TERT levels (95% vs 63%; P < 0.001 Fig. 3B). At multivariate anal-
ysis, high levels of TERT in tumor were significantly associated with a higher risk of regional failure (HR = 5.75, 
95% CI: 1.16–28.49; P = 0.032), increased risk of progression (HR:2.12,; 95% CI: 1.00–4.47; P = 0.049) and death 
(HR:3.53, 95% CI: 1.47–8.52; P = 0.005) (Table 2). TERT levels in SM and plasma were not associated with any 
time-to-event variables (Table 2).
Discussion
Data from this study confirm our previous observation, obtained from an independent series of patients13, that 
short telomeres in histologically normal SM are independently associated with a higher risk of mucosal failure. To 
investigate whether shortened telomeres in SM are the consequence of greater cell proliferation or are linked to 
the individual’s constitutive telomere length, we estimated telomere length in PBMC. Telomere length in PBMC 
is considered representative of an individual’s constitutive telomere length and correlates strongly with that in 
cells of different tissues, thus serving as a surrogate marker for other tissues17. In this series, while telomere length 
in PBMC did shorten with age thus showing normal telomeric dynamics, the lengths of telomeres in histologi-
cally normal mucosa surrounding UADT cancers did not correlate with patients’ ages or with telomere length in 
Figure 1. Distribution and median values of telomere length in tumor (A), surrounding mucosa (B) and 
peripheral blood mononuclear cells (PBMC) (C) according to age. Trend in values was tested through Analysis 
of Variance (ANOVA) with contrasts for linear trend.
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PBMC. Shortened telomeres in SM could therefore be a consequence of greater cell proliferation and/or environ-
mental and lifestyle-related factors such as tobacco smoking and alcohol consumption. Local tumor recurrence 
at the primary site can be due to residual cancer cells or to the development of second field tumors. The majority 
(94%) of patients undergoing primary surgical treatment in this study had clear margins, and none of the four 
cases with close or involved margins suffered local mucosal failure. This suggests that second field tumors might 
play a crucial role in mucosal failure. The model of field cancerization has recently been reviewed in molecu-
lar terms18. According to the model, precancerous fields characterized by genetic alterations due to carcinogen 
exposure can precede the emergence of synchronous or more frequently metachronous multiple cancer lesions. 
Part of this at-risk mucosa remains after the primary tumor has been treated and is the site of origin of subse-
quent lesions18,19. A more recent investigation found that the majority of the genomic changes, i.e. copy number 
Figure 2. Kaplan-Meier estimates of mucosal control (A), regional control (B), distant control (C), 
progression-free survival (D) and overall survival (E) according to telomere length in surrounding mucosa.
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alterations and point mutations, driving oral carcinogenesis take place in the pre-cancerous condition through 
gradual casual accumulation rather than as a consequence of a dramatic single event20.
Interestingly, patients exposed to tobacco and alcohol had shorter telomeres in histologically normal SM with 
the association being statistically significant in ever drinkers. Overall, the comparison of telomere length in adja-
cent mucosa and in PBMC in respect to age indicates that the phenotypically normal mucosa surrounding the 
tumor constitutes an acquired telomere-shortened epithelial field prone to genetic instability. This hypothesis is 
supported by findings of previous investigations that observed the presence of TP53 mutations in the field of mac-
roscopically normal mucosa surrounding HNSCC in more than one-third of patients21 and the generation, due 
to telomere dysfunction in TP53 mutant mice, of non-reciprocal translocations initiating the neoplastic process 
and accelerating carcinogenesis22.
Furthermore, we found that short telomeres in SM are associated with a worse response to multimodal ther-
apy, including disease progression during treatment. According to some studies18,19, the cancer cells of the pri-
mary tumor and the genetically unstable cells of the SM belong to a common pre-neoplastic field. Most patients 
treated with radical surgical resection of the tumor show genetically altered margins upon molecular analysis, 
and appear to be at high risk of disease progression since the genetically altered mucosa surrounding the primary 
tumor progressively transforms. Other theories argue that disease progression is due to the acquired migratory 
capacity of the neoplastic cells through the submucosa or to their excretion in the lumen of a hollow organ (e.g. 
UADT) with subsequent regrowth in nearby locations23,24. Confirmation of these results and determination of 
their clinical implications might lead to more aggressive therapeutic strategies, more accurate evaluation of the 
disease response under therapy, and a stricter and more personalized follow-up regime in patients with shorter 
telomeres in SM. Although there is evidence that telomere function can influence radiosensitivity15,16 it was not 
possible to assess this in our clinical cohort because most of patients received (chemo)radiotherapy as upfront 
treatment, or as adjuvant therapy following surgical treatment and the small number of patients treated by sur-
gery alone did not allow to explore this hypothesis.
Patients
Mucosal failureb Regional failure Distant failure Progression Death
n HR (95% CI) n HR (95% CI) n HR (95% CI) n HR (95% CI) n HR (95% CI)
Telomere length in tumor
<1.0475 51 12 Ref 9 Ref 1 Ref 17 Ref 15 Ref





p = 0.138 p = 0.475 p = 0.07 p = 0.271
Telomere length in surrounding mucosa
≥1.0675 47 7 Ref 6 Ref 2 Ref 15 Ref 12 Ref





p = 0.044 p = 0.362 p = 0.849 p = 0.285 p = 0.525
Telomere length in PBMC
≥0.878 30 5 Ref 4 Ref 2 — 7 Ref 5 Ref





p = 0.577 p = 0.878 p = 0.700 p = 0.779
TERT level in tumor
<1318 46 9 Ref 2 Ref 0 Ref 13 Ref 8 Ref





p = 0.233 p = 0.032 p = 0.049 p = 0.005
TERT level in surrounding mucosa
<441 44 11 Ref 6 Ref 1 Ref 17 Ref 13 Ref
≥441 43 14 1.03 (0.41–2.57) 11 1.46 (0.43–4.88) 4 1.86 (0.16–21.32) 20 0.91 (0.4–1.91) 17
1.25 
(0.56–2.75)
p = 0.948 p = 0.544 p = 0.618 p = 0.804 p = 0.587
TERT level in plasma
0 40 11 Ref 5 Ref 2 Ref 15 Ref 13 Ref





p = 0.824 p = 0.310 p = 0.623 p = 0.972 p = 0.239
Table 2. Hazard ratio (HR) and corresponding 95% confidence interval (CI)a for mucosal failure, regional 
failure, distant failure, progression, and death according to strata of telomere length and telomerase reverse 
transcriptase (TERT) level. aEstimated from Cox proportional hazard model, adjusting for gender, age, cancer 
site, stage, and surgery. bPatients without complete response were considered recurred after 91days from end of 
treatment, if no earlier recurrence was reported. PBMC = Peripheral blood mononuclear cells.
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Tumors harboring higher TERT levels were more frequently diagnosed in advanced stage and associated with 
the involvement of the regional lymph nodes. Moreover, risk of regional failure, progression, and death were inde-
pendently associated with high levels of TERT thus confirming previous data showing that TERT levels in cancer 
tissue increase with the aggressiveness of the disease10,13,25,26. This association may be attributable to telomerase’s 
non-canonical functions which are implicated in regulating several cancer hallmarks including cell proliferation, 
resistance to apoptosis, invasion, and metastasis by interaction of TERT with important cancer-related signaling 
cascades, such as Wnt/β-catenin and NF-kB pathways10,27. The activation of NF-kB signaling pathway by TERT 
stimulates the epithelial-to-mesenchymal transition that provides cancer cells with a more migratory mesen-
chymal phenotype12. High tumor TERT levels also correlate with a worse response to treatment, and it has been 
demonstrated that TERT confers resistance to different apoptotic stimuli including treatment with chemothera-
peutic agents and radiation28–30. Accordingly, TERT inhibition, through activation of DNA damage response non 
related to telomere shortening, sensitizes cells to the pro-apoptotic effect of chemotherapeutic drugs31. Thus, it is 
Figure 3. Kaplan-Meier estimates of mucosal control (A), regional control (B), distant control (C), 
progression-free survival (D) and overall survival (E) according to TERT level in tumor.
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conceivable to attribute the negative predictive value of TERT levels to its previously discussed extra-telomeric 
properties. Furthermore, patients with HPV-driven oropharyngeal cancer had higher levels of TERT in SM. 
This observation may be related to the topographic restriction of HPV-driven HNSCC to the lymphoepithelial 
tissue of the palatine tonsils and base of the tongue, potentially characterized by lymphocytes overexpressing 
TERT13,32,33, that with high probability could have been collected when the sampling of the mucosa surrounding 
the oropharyngeal carcinomas was performed.
Circulating cell-free TERT mRNA levels have been found to be higher in cancer patients with respect to 
controls, as well as independent markers of tumor response, and prognostic of disease progression in cancers 
frequently presenting with high tumor mass, e.g. gastric and colorectal cancer25,34,35. In the present study, we 
failed to find an association between plasma TERT levels and outcome variables. This negative result may be due 
to the low tumor volume and the greater propensity of HNSCC to spread along lymphatic channels rather than 
hematogenous routes36. In a substantial fraction of cases it was not possible to detect specific TERT mRNA in the 
plasma. It has been proposed that plasma circulating TERT levels could derive from activated lymphocytes and 
therefore they may be indicative of the induction of tumor immune responses37. Further studies are needed to 
clarify the significance and the role of circulating TERT levels in HNSCC.
In conclusion, high levels of TERT transcripts in cancer cells represent a reliable prognostic marker for iden-
tifying HNSCC patients with worse response to treatment and risk of progression. The different behavior of 
telomere length in adjacent mucosa and PBMC in respect to age suggests that in a subset of patients the phe-
notypically normal mucosa surrounding the tumor constitutes an acquired telomere-shortened epithelial field 
prone to genetic instability. These observations may lead to new perspectives in risk stratification, treatment, and 
surveillance strategies in patients with HNSCC.
Methods
Patients. In total, 101 consecutive newly diagnosed patients with histologically confirmed HNSCC (larynx, 
oral cavity, oropharynx and hypopharynx) were included in this prospective cohort study from 2012 to 2017. Due 
to differing epidemiology, etiology, histology and management, patients with nasopharyngeal carcinoma were 
excluded. Irrespective of HPV status, a multidisciplinary team decided on treatment planning according to TNM 
staging. Most T1 and T2 HNSCCs were treated with function-preserving surgery or definitive radiotherapy. Most 
patients with T3 and T4 tumors underwent radical surgery followed by post-operative (chemo)-radiotherapy 
depending on the presence of adverse features, or upfront chemoradiation. The local institutional review board 
approved the study protocol (“Comitato Etico Sperimentazione Clinica per le Province di Treviso e Belluno”, 
Italy; ethic vote: 346/AULSS9) and all patients gave their informed consent. We confirm that all experiments were 
performed in accordance with relevant guidelines and regulations. Along with the blood sample, two solid tissue 
samples were collected from each patient before treatment, one from a non-necrotic area of the carcinoma, and 
the other from SM. A UADT fiberoptic evaluation as well as computed tomography (CT) and/or magnetic res-
onance imaging (MRI) of the primary tumor and the neck were carried out 8–12 weeks after treatment to assess 
tumor response. The routine follow-up program consisted of locoregional examination including UADT endos-
copy at 2-month intervals during the first year, 3-month intervals in the second year, 4-month intervals between 
the third and fifth year, and every 6 months thereafter.
Tissue samples. Tissues samples from both tumor and SM were obtained before treatment. Surgeons were 
also requested to biopsy uninvolved mucosa at around 4 cm from the tumor margins depending on anatomical 
location. Precautions were taken to not contaminate the SM with tumor samples by changing surgical blades each 
time before cutting tissue. SM tissue was available for 96 patients. Both samples were snap-frozen in liquid nitro-
gen and stored at −80 °C until analysis. Cryostat sections, 6 microns thick, from each tissue sample were prepared 
using a 1720 Digital cryostat (Leitz, Germany). One section of each sample was stained with haematoxylin-eosin 
for histopathology. SM was histologically assessed and, in all cases, no histopathological alterations were found. 
For each tumor and SM sample, 5 or 6 cryostat sections were collected into two different 2 mL eppendorf tubes 
and stored at −80 °C and −20 °C respectively, for RNA and DNA extraction. DNA was extracted by the stand-
ard phenol/chloroform method, while RNA was extracted with Trizol reagent (Life Technologies, Carlsbad, CA, 
USA) and reverse-transcribed into cDNA using the SuperScript TM III RNase reverse trancriptase assay (Thermo 
Fisher Scientific, Waltham, MA, USA), according to the manufacturer’s instructions.
Peripheral blood samples. Plasma and PBMC samples were obtained, before treatment, from 6 mL of 
peripheral blood by Ficoll Paque (GE Healthcare, Chicago, IL, USA) protocol, and stored at −80 °C and −20 °C 
respectively, until use. DNA for telomere length analysis was extracted from PBMC by the standard phenol/
chloroform method, while the circulating mRNA for the quantification of TERT transcripts was extracted from 
plasma samples as previously described34, with the only modification that in this series of samples we started 
from 1 ml instead of 500 μL of plasma and all reagent quantities were adjusted accordingly. RNA was reverse tran-
scribed into cDNA using the SuperScript TM III RNase reverse trancriptase assay (Thermo Fisher Scientific) in a 
final volume of 80 μL, according to the manufacturer’s instructions.
Quantification of TERT transcripts in tissue and plasma samples. The level of TERT tran-
scripts was quantified by real-time PCR, as previously described25 with some modifications. In particular, a 
new primer pair was designed in order to reduce the length of the amplified product, thus improving detec-
tion of the cDNA target sequence38,39. Primers AT1 (5′-CGGAAGAGTGTCTGGAGCAA-3′) and AT2b 
(5′-CGCAGCTGCACCCTCTTCA-3′) were designed on exon 3 and 4 respectively; they bind to nucleotide 
sequences located upstream of the RT motif 1 on the TERT gene allowing amplification of all TERT transcripts 
producing an amplified product of 68 bp34. Values of TERT were normalized for 103 copies of HPRT1. For 
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plasma samples, levels of TERT mRNA were also estimated per mL using the conversion factor x 8 as previously 
described34.
Telomere length measurement. Relative telomere length was determined on DNA extracted from tissues 
and PBMC by multiplex quantitative Real-time PCR, as previously described40,41, with minor modifications. In 
particular, each PCR reaction was performed in a final volume of 25 μL, containing 5 μL sample (10 ng DNA) and 
20 μL master-mix ready-to-use 1X Light Cycler 480 SYBR Green I (Roche Life Science, Penzberg, BY, Germany), 
containing 900 nmol/L of each primer. Sequences of telomere and albumin primers are detailed in a previous 
study40. The thermal cycling profile was 15 min at 95 °C, two cycles of 15 s at 94 °C, 15 s at 51 °C, followed by 40 
cycles of 15 s at 94 °C, 10 s at 62 °C, 15 s at 74 °C, 10 s at 84 °C, 15 s at 89 °C, with signal acquisition at the end of 
both the 74 °C and 89 °C steps. After cycling, a melting curve program was run starting with a 95 °C incuba-
tion for 1 minute, followed by continuous acquisitions every 0.2 °C for 45 °C to 95 °C (ramping at 0.11 °C/s). A 
standard curve was generated at each PCR run, consisting of DNA from the RAJI cell line, serially diluted from 
10 to 0.41 ng/µl42. All DNA samples and reference samples were run in triplicate. LightCycler raw text files were 
converted using the LC480Conversion free software (http://www.hartfaalcentrum.nl/index.php?main=files&-
fileName=LC480Conversion.zip&description=LC480Conversion:%20conversion%20of%20raw%20data%20
from%20LC480&sub=LC480Conversion), and the converted data were analysed using LinRegPCR free soft-
ware43. Telomere length values were calculated as telomere/single-copy gene (T/S) ratio, as previously described42.
Statistical analysis. Telomere length in tumor, SM, PBMC according to age groups were displayed 
by beeswarm plots. The association between telomere length and age was tested through the analysis of var-
iance (ANOVA) with contrasts for linear trend. Differences in telomere length and TERT level according to 
socio-demographic and clinical characteristics were tested with the Kruskall-Wallis test.
The association between telomere lengths, TERT levels, and treatment response was evaluated by calculating 
the odds ratio (OR) of partial response or disease progression versus complete response through unconditional 
logistic regression model. OR and 95% corresponding confidence intervals (CI) were adjusted for gender, and 
potential clinical confounders (namely, cancer site, stage, and surgery).
The impact of telomere length and TERT levels on survival outcomes was evaluated through survival analysis, 
comparing patients with telomere length and TERT levels under (low) or above (high) tissue-specific median 
values. For each patient, person-time at risk was computed from the date of last treatment to the event date or 
the date of last follow-up, whichever came first. Event was defined as cancer reappearance at the UADT site for 
mucosal control; neck lymph node failure for regional control; distant metastasis for distant control; mucosal, 
regional or distant recurrence or death for progression-free survival; death for overall survival. The Kaplan-Meier 
method was used to generate crude survival curves and the log-rank test was used to assess the heterogeneity 
in time to event in strata of selected covariates44, censoring follow-up at 5 years. Hazard ratios (HR) and the 
corresponding 95% CI were calculated using Cox proportional hazards models44, adjusting for gender, age, and 
potential confounders (namely cancer site, stage, and surgical treatment).
Data availability
The datasets generated during and/or analyzed during the current study are available from the corresponding 
author on reasonable request.
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